Bills · H.R. 10919 · Text
Introduced in House
Confirmed from the official record
Our copy of the file on govinfo.gov, saved November 13, 2026. Fingerprint (SHA-256): 41996787e463ce63.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 10919 Introduced in House (IH)]
<DOC>
119th CONGRESS
2d Session
H. R. 10919
To amend title III of the Public Health Service Act to ensure that
certain safety net providers are not required to pay more than the 340B
ceiling price for covered outpatient drugs at the time of purchase.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
October 29, 2026
Mr. Bergman (for himself, Mr. Ruiz, Mr. Cleaver, Mr. Mann, Ms. Titus,
Ms. Norton, Ms. Davids of Kansas, Ms. Balint, Mr. Golden of Maine, Mr.
Moulton, Mr. Hernandez, Ms. Stansbury, Mr. Austin Scott of Georgia, and
Mr. Newhouse) introduced the following bill; which was referred to the
Committee on Energy and Commerce
_______________________________________________________________________
A BILL
To amend title III of the Public Health Service Act to ensure that
certain safety net providers are not required to pay more than the 340B
ceiling price for covered outpatient drugs at the time of purchase.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Safety Net Provider Drug Pricing
Protection Act''.
SEC. 2. ENSURING UPFRONT 340B DISCOUNTED PRICING FOR CERTAIN SAFETY NET
PROVIDERS.
(a) In General.--Section 340B(a) of the Public Health Service Act
(42 U.S.C. 256b(a)) is amended by adding at the end the following new
paragraph:
``(11) Upfront discounted pricing for certain safety net
providers.--
``(A) In general.--The Secretary may not enter into
an agreement with a manufacturer of covered outpatient
drugs under paragraph (1) under which the amount
required to be paid to the manufacturer for covered
outpatient drugs by a safety net covered entity
exceeds, at the point of purchase of such drug, the
applicable ceiling price for such drug (as described in
paragraph (1)).
``(B) Safety net covered entity.--For purposes of
subparagraph (A), the term `safety net covered entity'
means a covered entity that--
``(i) is described in any of subparagraphs
(A), (D), (F), (G), (H), (I), (J), or (N) of
paragraph (4);
``(ii) is an entity described in
subparagraph (K) of such paragraph that
receives funds directly from a State or unit of
local government; or
``(iii) is a sole community hospital
described in subparagraph (O) of such
paragraph.''.
(b) Rule of Construction.--Nothing in this section, or the
amendment made by this section, shall be construed to permit under
paragraph (1) of section 340B(a) of the Public Health Service Act (42
U.S.C. 256b(a)) any arrangement under which a safety net covered entity
(as defined in paragraph (11)(B) of such section) pays to the
manufacturer of a covered outpatient drug an amount in excess of the
applicable ceiling price for such drug (as described in such paragraph
(1)) at the time of purchase, with later reconciliation by rebate,
reimbursement, or other payment.
(c) Effective Dates.--
(1) In general.--The amendments made by this section shall
take effect on the date of the enactment of this section and
shall apply to drugs purchased on or after the date of the
enactment of this section.
(2) Application to existing agreements.--Beginning on the
date of the enactment of this section, the amendments made by
this section shall be taken into account in determining whether
an agreement with a manufacturer of covered outpatient drugs
meets the requirements of section 340B(a) of the Public Health
Service Act (42 U.S.C. 256b(a)).
<all>